Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Issue 5 (May 2016)

• Record Type: Journal Article
• Authors: Kallini, Joseph; Gabr, Ahmed; Salem, Riad; Lewandowski, Robert
• Is Part Of: Advances in therapy. Volume 33:Issue 5(2016)
• Page Start: 699
• Page End: 714
• Publication Date: 2016-05
• Subjects: Hepatocellular carcinoma (HCC) -- Oncology -- Radioembolization -- Transarterial radioembolization (TARE) -- Yttrium-90 (Y90); Diagnosis -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1007/s12325-016-0324-7
• Languages: English
• ISSNs: 0741-238X

Abstract

Abstract Background Hepatocellular carcinoma (HCC) is a common cause of worldwide mortality. Transarterial radioembolization (TARE) with yttrium-90 (Y90), a transcatheter intra-arterial procedure performed by interventional radiology, has become widely utilized in managing HCC. Methods The following is a focused review of TARE covering its commercially available products, clinical considerations of treatment, salient clinical trial data establishing its utility, and the current and future roles of TARE in the management of HCC. Results TARE is indicated for patients with unresectable, intermediate stage HCC. The two available products are glass and resin microspheres. All patients undergoing TARE must be assessed with a history, physical examination, clinical laboratory tests, imaging, and arteriography with macroaggregated albumin. TARE is safe and effective in the treatment of unresectable HCC, as it has a safer toxicity profile than chemoembolization, longer time-to-progression, greater ability to downsize and/or bridge patients to liver transplant, and utility in tumor complicated by portal vein thrombosis. TARE can also serve as an alternative to ablation and chemotherapy. Conclusion TARE assumes an integral role in the management of unresectable HCC and has been validated by numerous studies.